What's on the label is the measured result — net peptide mass, not gross powder weight, plus RP-HPLC purity, on a lot-numbered COA for every batch.
Net peptide mass and RP-HPLC purity — a lot-numbered COA for every batch.
Net peptide mass + HPLC purity, per lot.
PCAC will review 7 peptides for the 503A bulks list, BPC-157, KPV, TB-500, MOTS-c, Emideltide, Semax, Epitalon. Read our briefing →
PCAC will review 7 peptides for the 503A bulks list. Read →
FDA PCAC reviews 7 peptides in July. Read →
Gonadotropin glycoprotein hormone · heavily regulated
PeptideXpo buyer fit
This PeptideXpo page is intentionally positioned for distributors, OEM buyers, and procurement teams comparing HCG (Human Chorionic Gonadotropin) inside a wider peptide catalog. It is not trying to be the deepest single-molecule monograph; the differentiated intent is assortment planning, export-ready documentation, fill-size comparison, and whether this SKU belongs in a broader buyer program.
Overview
Human Chorionic Gonadotropin (HCG) is a heterodimeric glycoprotein hormone produced natively by the syncytiotrophoblast cells of the placenta during pregnancy. The molecule consists of a 92-amino-acid alpha-subunit (shared with FSH, LH, and TSH) non-covalently associated with a 145-amino-acid HCG-specific beta-subunit, both heavily glycosylated. HCG mimics LH activity at the LH/HCG receptor and is approved as a prescription drug for ovulation induction, hypogonadotropic hypogonadism in males, and undescended testicles in pediatric patients. Bulk HCG is sourced either from purified pregnancy urine (the classical method) or from recombinant cell-culture expression, the two source types differ in glycan structure and require source-specific identity confirmation. PeptideXpo distributes HCG only to qualified buyers with appropriate licensing. The eight standard fill sizes span both IU-based (1000-10000 IU) and mass-based (1-10 mg) presentations to accommodate the dual conventions used in compounding pharmacy and research workflows. The release packet emphasizes biological activity (in IU per mg by bioassay) rather than chemical purity alone, because the heterodimer integrity and glycosylation pattern affect potency in ways that chromatographic purity does not capture.
Specifications
Documentation available on request
Regulatory note
Highly regulated heterodimeric glycoprotein hormone. Sold only to qualified buyers with appropriate licensing in their jurisdiction. Order requires compliance review.
Frequently asked questions
HCG is dosed in International Units (IU) for clinical applications because the biological activity of glycoprotein hormones depends on glycosylation pattern as much as protein mass, the same mass of HCG from different sources can have different biological activity, so the IU bioassay-based unit is the operational standard for clinical dosing. For purified urinary-derived HCG (the material supplied here) the specific activity is on the order of 1 mg ≈ 6000 IU; recombinant HCG runs higher (~26,000 IU/mg). Batch-specific bioassay verification is the operative number on the COA. Both unit conventions are supplied (IU-based fills for clinical workflows; mg-based fills for research workflows that prefer mass-based dosing) to accommodate the dual conventions used in the market.
Urinary HCG (uHCG) is purified from the urine of pregnant women, the historical source of HCG since the 1930s. Recombinant HCG (rHCG) is produced by recombinant cell-culture expression. Both have the same protein backbone but differ in glycosylation pattern: uHCG is more heavily glycosylated (the kidneys preferentially excrete the more-glycosylated isoforms during pregnancy), while rHCG has a more uniform glycan profile from controlled cell-culture conditions. The clinical pharmacokinetics differ, uHCG has slightly longer plasma half-life due to the heavier glycosylation. Both forms are approved as prescription drugs in major markets; the choice between them depends on the specific clinical protocol and supply availability.
HCG is approved for several distinct clinical indications with substantially different dosing protocols. **Ovulation induction**: 5,000-10,000 IU IM single-dose to trigger follicular rupture after FSH/HMG priming. **Hypogonadotropic hypogonadism in males**: 1,000-4,000 IU IM 2-3× weekly to stimulate testicular testosterone production. **Cryptorchidism (undescended testicles)**: 500-4,000 IU IM 2-3× weekly for 2-6 weeks in pediatric patients. **Assisted reproductive technology**: variable protocols depending on the specific cycle. The 1,000 IU, 2,000 IU, 5,000 IU, and 10,000 IU fill sizes in our catalog cover these various clinical dose ranges. The mass-based fills (1-10 mg) target research and compounding workflows where the IU-based clinical convention isn't operationally needed.
Related peptides
